Pure Akkermansia

Why strain identity is everything

The species name Akkermansia muciniphila tells you almost nothing about what you are actually getting. A landmark 2023 study published in Food Science and Human Wellness tested six different Akkermansia strains head-to-head in both animal and cell models. The results were stark: some strains showed strong, significant protection of the gut barrier — others showed no significant effect at all. Strain GD49, for example, failed to meaningfully restore tight junction proteins ZO-1, Occludin, or Claudin-1 under inflammatory conditions. Strain JL50 — which carries the same surface protein genes as AH39 — outperformed it on every single measure.

Generic Akkermansia labelling gives you no assurance of which category your supplement falls into. AH39 is identified, studied, and verified.

What makes AH39 different

The AH39 strain carries specific functional genes — including COG0438, COG0463, and COG2244 — that are directly involved in the synthesis of outer membrane surface proteins. These proteins are the active mechanism through which Akkermansia muciniphila communicates with the gut epithelium and the mucosal immune system. Strains that lack these genes show significantly weaker gut barrier effects in head-to-head comparisons (Liu et al., 2023).

The surface proteins of AH39 have also been shown to act as cognate antigens for T cell receptors in mesenteric lymph node tissue — meaning AH39 does not just sit in your gut passively; it actively educates your gut immune system. Research using the AH39 strain demonstrated direct induction of interleukin-10 secretion and regulatory T cell activity in both the mesenteric lymph nodes and spleen of conventional and germ-free mice (Feng et al., 2022).

The clinical evidence — what happened in the human trial

In 2025, a randomised, double-blind, placebo-controlled trial published in Clinical Nutrition ESPEN (Aalipanah et al.) delivered AH39 in postbiotic format via fortified yogurt to overweight and obese adults over 8 weeks. Compared to the placebo group, the AH39 group showed:

Significantly reduced waist circumference (P = 0.003) Significantly reduced waist-to-height ratio (P = 0.004) Significantly reduced body fat percentage (P = 0.032) Significantly reduced AST liver enzyme levels (P = 0.045) Significantly reduced appetite scores (P = 0.047)

No adverse effects were recorded. The postbiotic format — heat-inactivated bacteria — delivered these outcomes without requiring live bacterial viability, confirming that the bioactivity resides in the structural surface proteins rather than metabolic output.

Why your Akkermansia levels are probably low

Akkermansia muciniphila is one of the most environmentally sensitive species in the gut microbiome. Its abundance is significantly reduced by high-fat and low-fibre diets, antibiotic use even after a single course, obesity and metabolic syndrome, chronic gut inflammation and IBD, heavy metal and environmental pollutant exposure, and ageing.

Research has consistently found that people with obesity, type 2 diabetes, atherosclerosis, and inflammatory bowel conditions carry significantly lower Akkermansia levels than healthy controls. Supplementing with AH39 directly addresses this deficit — replenishing a species that modern diet and lifestyle actively depletes.

Features at a glance

Strain-identified: Akkermansia muciniphila AH39 — the same strain used across all published research Postbiotic format: heat-inactivated for stability and safety, no refrigeration required, no live bacteria risk Single ingredient: no fillers, no blending, no dilution with inferior strains Flexible dosing: powder format — mix into water, yogurt, or a smoothie. The 2025 RCT used yogurt as the delivery vehicle Surface protein bioactivity: outer membrane proteins interact directly with gut epithelial and immune cells — the mechanism behind the clinical outcomes Research-verified production: cultured using brain heart infusion medium with porcine gastric mucin, the validated method used across all published AH39 studies No artificial sweeteners, no maltodextrin, no excipients

Benefits

Gut barrier integrity AH39 surface proteins directly regulate the expression of tight junction proteins ZO-1, Occludin, and Claudin-1 — the molecular structures that maintain a sealed gut wall and prevent undigested particles and bacterial endotoxins from entering the bloodstream. Comparative strain research confirmed that only strains carrying the correct surface protein genes produce this effect. AH39 carries them. (Liu et al., 2023)

Body composition support The 2025 human RCT found significantly greater reductions in waist circumference and body fat percentage in the AH39 group versus placebo after 8 weeks, without any changes to diet or physical activity protocols between groups. The proposed mechanism involves increased acetate production by Akkermansia, which suppresses appetite and reduces metabolic inflammation. (Aalipanah et al., 2025)

Liver health Alongside body composition changes, the AH39 group showed significantly reduced AST liver enzyme levels — a marker of hepatic stress. The proposed mechanisms include reduced intrahepatic triglyceride deposition, improved intestinal homeostasis, and stimulation of beta-oxidation. (Aalipanah et al., 2025)

Appetite regulation Appetite scores were significantly lower in the AH39 group versus placebo at the end of the 8-week trial. This is consistent with the known role of gut microbiota in regulating the gut-brain axis and modulating satiety hormone signalling, including peptide YY and glucagon-like peptide-1. (Aalipanah et al., 2025)

Gut immune education AH39 is one of a very small number of gut species demonstrated to directly activate an adaptive immune response via the mesenteric lymph nodes. Its surface proteins function as cognate T cell receptor antigens — stimulating regulatory T cell activity and interleukin-10 production. This positions AH39 not just as a gut barrier supplement but as an active participant in mucosal immune homeostasis. (Feng et al., 2022)

Microbiome ecosystem support Beyond its direct effects, oral AH39 administration has been shown to influence the broader gut microbial community — particularly taxa in the Clostridiales order, including known butyrate producers. Akkermansia supports trophic interactions with species like Anaerostipes caccae, whose butyrate output further benefits the gut epithelium. (Feng et al., 2019)

Safe and well-tolerated As a postbiotic, Pure Akkermansia Powder carries none of the risks associated with live bacterial supplementation. No adverse effects were observed in any of the clinical studies referenced. Suitable alongside existing supplement and medication regimens — but consult your healthcare provider if you are immunocompromised.

Published research

Liu Y. et al. (2023). Strain-specific effects of Akkermansia muciniphila on intestinal barrier regulation. Food Science and Human Wellness, 12, 1526–1537. https://doi.org/10.1016/j.fshw.2023.02.022

Feng S. et al. (2022). Species- or genus-dependent immunostimulatory effects of gut-derived potential probiotics. Journal of Genetics and Genomics. https://doi.org/10.1016/j.jgg.2022.11.001

Feng S. et al. (2022). Characteristics of an in vitro mesenteric lymph node cell suspension model. International Journal of Molecular Sciences, 23, 1003. https://doi.org/10.3390/ijms23021003

Feng S. et al. (2019). Influence of oral administration of Akkermansia muciniphila on gut microbiota composition. FEMS Microbiology Letters, 366, fnz160. https://doi.org/10.1093/femsle/fnz160

Aalipanah E. et al. (2025). Comparing effects of yogurt containing Akkermansia muciniphila postbiotic vs Lactobacillus rhamnosus postbiotic. Clinical Nutrition ESPEN, 68, 438–446. https://doi.org/10.1016/j.clnesp.2025.05.045

These statements are based on published scientific research. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional if you have an existing medical condition.